Hyperpigmentation — overproduction of melanin producing dark spots, patches, or general uneven skin tone — is one of the most common dermatological concerns globally, disproportionately affecting individuals with darker Fitzpatrick skin types (III–VI) who produce more melanin and have higher risk of post-inflammatory hyperpigmentation (PIH) from acne, procedures, or injury. Understanding the distinction between melasma, PIH, solar lentigines, and other forms of hyperpigmentation guides treatment selection — they share the same mechanism (melanin overproduction) but have different triggers, locations, and treatment timelines. Our skin care catalog carries clinical-grade depigmenting agents and brightening products.
Treatment Evidence Hierarchy
Hydroquinone (HQ): the gold standard prescription depigmenting agent, inhibiting tyrosinase (the rate-limiting enzyme in melanin synthesis) at 2–4%. Prescription 4% HQ remains the most effective single topical depigmenting agent in RCTs for melasma and PIH, with significant response in 75–85% of patients over 12 weeks. Concerns: potential ochronosis (rare, permanent bluish discoloration with prolonged high-concentration use), FDA's 2006 categorization request for more safety data (resulting in OTC HQ being removed from US market in 2020 — available prescription-only). Kojic acid: fungal-derived tyrosinase inhibitor, 1–4% — evidence of modest depigmenting efficacy; phototoxicity and sensitization limit tolerability. Azelaic acid 15–20%: selective melanocyte cytotoxicity with tyrosinase inhibition — particularly well-suited for PIH in darker skin types with low risk of paradoxical hyperpigmentation. Tranexamic acid (TXA): emerging evidence from multiple RCTs showing TXA 2–5% topical or 250mg oral twice daily significantly reduces melasma, with mechanism involving inhibition of keratinocyte-to-melanocyte plasminogen activator signaling.
Retinoids and Vitamin C as Combination Partners
Tretinoin 0.05–0.1% has direct depigmenting effects through keratinocyte accelerated turnover (reducing the time melanin-laden cells reside in the epidermis) and direct inhibition of tyrosinase expression. The Kligman formula (tretinoin 0.05% + HQ 4% + hydrocortisone 0.1%) remains the most evidence-supported combination for melasma, though its prescription-only status limits accessibility. Vitamin C (LAA 10–20%) as a standalone or combination ingredient inhibits tyrosinase through copper chelation and reduction of oxidized DOPA, with evidence for both solar lentigo lightening and melasma improvement. Our skin care section includes brightening serums and targeted hyperpigmentation products incorporating evidence-based ingredients.
Photoprotection: The Non-Negotiable Component
UV exposure stimulates melanogenesis through MSH and ACTH signaling — without strict sun protection, any depigmenting treatment is fighting an uphill battle. Broad-spectrum SPF 50+ (with UVA protection) applied daily is required for any hyperpigmentation treatment to be effective. For melasma specifically, visible light may also trigger melanogenesis — tinted mineral sunscreens with iron oxides that block visible light provide superior melasma control compared to UV-only sunscreens in RCTs.
